Cargando…
Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496259/ https://www.ncbi.nlm.nih.gov/pubmed/32567214 http://dx.doi.org/10.1002/hec.4120 |
_version_ | 1783583058077679616 |
---|---|
author | Peltonen, Juhana Johansson, Edvard Wincent, Joakim |
author_facet | Peltonen, Juhana Johansson, Edvard Wincent, Joakim |
author_sort | Peltonen, Juhana |
collection | PubMed |
description | Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms through medication. Although this development has led to many positive outcomes, the broader societal implications are still poorly understood. In particular, person‐level studies suggest that ADHD‐like behavior may possess some advantages for engaging in entrepreneurship and the initiation of new businesses, which is considered a key activity for economic development. Using recent panel data from 11 countries and one special administrative region (SAR), we investigate if the increasing use of ADHD medication in adults is associated with an unintended outcome of reducing entrepreneurship. We find that a roughly one unit increase in the prevalence of adult ADHD medication is associated with a one unit decrease in limited liability company registrations per working age population. In practical terms, the effect of a one within‐country/SAR standard deviation increase of adult ADHD medication prevalence corresponds to a decrease in new business formation of 20% of its mean in the sample. |
format | Online Article Text |
id | pubmed-7496259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74962592020-09-25 Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? Peltonen, Juhana Johansson, Edvard Wincent, Joakim Health Econ Health Economics Letters Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms through medication. Although this development has led to many positive outcomes, the broader societal implications are still poorly understood. In particular, person‐level studies suggest that ADHD‐like behavior may possess some advantages for engaging in entrepreneurship and the initiation of new businesses, which is considered a key activity for economic development. Using recent panel data from 11 countries and one special administrative region (SAR), we investigate if the increasing use of ADHD medication in adults is associated with an unintended outcome of reducing entrepreneurship. We find that a roughly one unit increase in the prevalence of adult ADHD medication is associated with a one unit decrease in limited liability company registrations per working age population. In practical terms, the effect of a one within‐country/SAR standard deviation increase of adult ADHD medication prevalence corresponds to a decrease in new business formation of 20% of its mean in the sample. John Wiley and Sons Inc. 2020-06-22 2020-09 /pmc/articles/PMC7496259/ /pubmed/32567214 http://dx.doi.org/10.1002/hec.4120 Text en © 2020 The Authors. Health Economics published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Health Economics Letters Peltonen, Juhana Johansson, Edvard Wincent, Joakim Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title | Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title_full | Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title_fullStr | Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title_full_unstemmed | Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title_short | Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
title_sort | does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? |
topic | Health Economics Letters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496259/ https://www.ncbi.nlm.nih.gov/pubmed/32567214 http://dx.doi.org/10.1002/hec.4120 |
work_keys_str_mv | AT peltonenjuhana doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship AT johanssonedvard doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship AT wincentjoakim doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship |